SCHEMBL2076907

SCHEMBL2076907

C1=NCC2CCNC2=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30707492 0.68 HRH3 (0.32)
SCHEMBL2397144 0.65
SCHEMBL312465 0.64
SCHEMBL16037385 0.62
SCHEMBL7860937 0.61
SCHEMBL4749576 0.60
SCHEMBL30915787 0.59
SCHEMBL19348395 0.59
SCHEMBL30196745 0.59
SCHEMBL473740 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3033342-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS Grünenthal GmbH (DE) 2016-06-22 EP claimed
WO-2015022073-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS Grünenthal GmbH (DE) 2015-02-19 WO claimed
EP-1432708-B1 PREPARATION AND USE OF 1,5,6,7-TETRAHYDROPYRROLO 3,2-C]PYRIDINE DERIVATIVES FOR TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORP (US) 2005-11-30 EP claimed
US-11339157-B1 4H-pyrrolo[3,2-c]pyridin-4-one derivatives BAYER AKTIENGESELLSCHAFT (DE) 2022-05-24 US disclosed
US-10821152-B2 Methods, agents and compositions for treatment of inflammatory conditions Betanien Hospital (NO) 2020-11-03 US disclosed
US-20170258867-A1 METHODS, AGENTS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY CONDITIONS KAASS DISCOVERY AS (NO) 2017-09-14 US disclosed
US-20160346255-A1 METHODS, AGENTS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY CONDITIONS ASTELLAS PHARMA INC. (JP) 2016-12-01 US disclosed
EP-3033342-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS Grünenthal GmbH (DE) 2016-06-22 EP disclosed
WO-2015022073-A1 ANNELATED PYRROLES AND THEIR USE AS CRAC INHIBITORS Grünenthal GmbH (DE) 2015-02-19 WO disclosed
US-7897771-B2 Fused heterocyclic compounds JANSSEN PHARMACEUTICA NV (BE) 2011-03-01 US disclosed
US-20090270370-A1 FUSED HETEROCYCLIC COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2009-10-29 US disclosed
EP-1937679-A2 PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS AstraZeneca AB (SE) 2008-07-02 EP disclosed
WO-2007039740-A2 PREPARATION AND USE OF TETRAHYDROPYRROLO [3, 2-C] PYRIDIN-4-ONE DERIVATIVES FOR TREATMENT OF OBESITY, PSYCHIATRIC AND NEUROLOGICAL DISORDERS ASTRAZENECA AB (SE) 2007-04-12 WO disclosed
US-7071207-B2 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2006-07-04 US disclosed
US-20060122215-A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2006-06-08 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed